Optimizing patient treatment decisions in an era of rapid technological advances: the case of hepatitis C treatment.
Authors:
Open Access
- 19 July 2015
- journal article
- research article
- Published by Springer Nature in Health Care Management Science
- Vol. 20 (1) , 16-32
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Cost-Effectiveness Analysis of Risk-Factor Guided and Birth-Cohort Screening for Chronic Hepatitis C Infection in the United StatesPLOS ONE, 2013
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2011
- Boceprevir for Untreated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Irreversible treatment decisions under consideration of the research and development pipeline for new therapiesIIE Transactions, 2010
- Diagnosis, management, and treatment of hepatitis C: An update # † ‡Hepatology, 2009
- Medical technology adoption, uncertainty, and irreversibilities: is a bird in the hand really worth more than in the bush?Health Economics, 2009
- The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002Annals of Internal Medicine, 2006
- Taking account of future technology in cost effectiveness analysisBMJ, 2004
- Optimal timing of technology adoptionJournal of Economic Dynamics and Control, 1998
- Technological expectations and adoption of improved technologyJournal of Economic Theory, 1984